**1. Introduction**

Cancer is a condition characterized by uncontrolled cell proliferation, avoiding growth suppressive factors, supporting cell death, allowing replicative immortality, driving angiogenesis, causing invasion and metastasis [1]. Breast cancer (BC) is the neoplasm with the highest frequency and mortality in women [2]. Prognosis and treatment depend on the type and stage of BC [3].

According to the treatment response, there are three subtypes of BC; hormone receptor-positive, human epidermal growth factor 2 (HER 2) positive, and triplenegative. Triple-negative breast cancer (TNBC) is a heterogeneous subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2). This cancer subtype accounts for 15–20% of women diagnosed with breast cancer [4]. It usually occurs in young, Hispanic and African-American patients [5]. Patients with TNBC have BRCA1/2 mutations, have a worse prognosis than any other cancer subtype due to high recurrence rates (being higher in the first 1–4 years of follow-up) and limited therapeutic options. Currently, the only systemic treatment for TNBC is chemotherapy [5]; however, this therapeutic option is not standardized [6]. Additionally, TNBC is usually more aggressive and more prone to metastasis [7–9]. Unfortunately, metastasis contributes to 90% of cancer-related deaths [10]. Owing to, it is necessary to look for alternative treatments that offer patients diagnosed with BC. This work presents disintegrins that have proven their effect on BC both *in vitro* and *in vivo.*
